---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039409"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:00:38.074276+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corbus Q2 net loss $8.8M vs $13.2M YoY; cash $36.6M; pipeline on track

## Summary
- Net loss of $8.8M ($2.05 diluted EPS) compared to $13.2M ($3.18) in Q2 2022; operating expenses down $4.1M.
- Cash, cash equivalents and investments $36.6M as of June 30, 2023; expected to fund operations through Q2 2024.
- CRB-701 Phase 1 dose escalation ahead of schedule in China; completion expected Q4 2023; US trial start accelerated to Q1 2024.
- Preliminary PK data for CRB-701 shows longer half-life and lower free MMAE vs published PADCEV data.
- CRB-601 IND submission on track for Q4 2023; first patient in Phase 1 expected H1 2024.

## SEC filing metadata
- accession: 0000950170-23-039409
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017023039409/0000950170-23-039409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017023039409/crbp-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039409
- JSON: https://secwatch.observer/filing/0000950170-23-039409.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039409.txt

## Key facts
- Earnings Releases
  Corbus Pharmaceuticals Holdings, Inc. reported the three months ended June 30, 2023 results: net income net loss of approximately $8.8 million, or a net loss per diluted share of $2.05, EPS $2.05.
  - Period: the three months ended June 30, 2023
  - Net income: net loss of approximately $8.8 million, or a net loss per diluted share of $2.05
  - EPS: $2.05
  - Result: reported results
  source text: The Company reported a net loss of approximately $8.8 million, or a net loss per diluted share of $2.05, for the three months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023039409/0000950170-23-039409-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.